PMID- 37195408 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231119 IS - 2193-8253 (Print) IS - 2193-6536 (Electronic) IS - 2193-6536 (Linking) VI - 12 IP - 4 DP - 2023 Aug TI - Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study. PG - 1171-1186 LID - 10.1007/s40120-023-00479-4 [doi] AB - INTRODUCTION: Intravenous immunoglobulin (IVIG) is recommended as first-line therapy for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), an immune-mediated neuropathy. The clinical profile of patients with CIDP newly initiating IVIG is poorly characterized. This claims-based cohort study describes characteristics of US patients with CIDP initiating IVIG treatment. METHODS: Adult immunoglobulin (IG)-naive patients with CIDP diagnosed between 2008 and 2018 and a subgroup of patients subsequently initiating IVIG were identified in the Merative MarketScan Research Databases. Demographics, clinical characteristics, and diagnostic procedures were described for patients initiating IVIG. RESULTS: Of 32,090 patients with CIDP identified, 3975 (mean age 57 years) subsequently initiated IVIG. In the 6 months prior to IVIG initiation, diagnoses of comorbidities including neuropathy (75%), hypertension (62%), and diabetes (33%) were frequent, as were CIDP features/symptoms/markers of functional status including chronic pain (80%), difficulty walking (30%), and weakness (30%). CIDP-related laboratory/diagnostic procedures were performed in approximately 20- > 40% of patients in the 3 months prior to IVIG initiation (63.7% underwent electrodiagnostic/nerve conduction testing in the 6 months prior to IVIG initiation). Patient characteristics by initial IVIG product differed only in IVIG initiation year, US geographic region, and insurance type. Comorbidities, CIDP severity or functional status markers, and other clinical variables were generally well balanced across initial IVIG product groups. CONCLUSION: A heavy burden of symptoms, comorbidities, and diagnostic testing exists in patients with CIDP initiating IVIG. Characteristics of patients with CIDP initiating different IVIG products are well balanced, suggesting an absence of clinical or demographic determinants underlying IVIG selection. CI - (c) 2023. The Author(s). FAU - Layton, J Bradley AU - Layton JB AUID- ORCID: 0000-0003-0994-5820 AD - RTI Health Solutions, Research Triangle Park, NC, USA. FAU - Ritchey, Mary E AU - Ritchey ME AUID- ORCID: 0000-0003-0304-9304 AD - RTI Health Solutions, Research Triangle Park, NC, USA. AD - Center for Pharmacoepidemiology and Treatment Sciences, Rutgers University, New Brunswick, NJ, USA. FAU - Huang, Zhongwen AU - Huang Z AD - Takeda Development Center Americas, Inc., 650 E. Kendall St., Cambridge, MA, 02142, USA. FAU - Chavan, Shailesh AU - Chavan S AD - Takeda Development Center Americas, Inc., 650 E. Kendall St., Cambridge, MA, 02142, USA. FAU - Ay, Hakan AU - Ay H AD - Takeda Development Center Americas, Inc., 650 E. Kendall St., Cambridge, MA, 02142, USA. FAU - Souayah, Nizar AU - Souayah N AUID- ORCID: 0000-0003-3873-3448 AD - Department of Neurology, Rutgers University, Newark, NJ, USA. FAU - Anderson-Smits, Colin AU - Anderson-Smits C AUID- ORCID: 0000-0002-2734-6154 AD - Takeda Development Center Americas, Inc., 650 E. Kendall St., Cambridge, MA, 02142, USA. Colin.andersonsmits@takeda.com. LA - eng PT - Journal Article DEP - 20230517 PL - New Zealand TA - Neurol Ther JT - Neurology and therapy JID - 101637818 PMC - PMC10310640 OAB - Intravenous immunoglobulin, also called IVIG, involves giving antibodies through a drip into a vein. IVIG is recommended as one of the first treatments that patients receive if they have chronic inflammatory demyelinating polyradiculoneuropathy, also called CIDP, which is a rare disease that causes the body's immune system to attack its nerves. Our study described the characteristics of patients with CIDP who received IVIG in the USA. Information was collected from a large health insurance database and included records of patients aged >/= 18 years who were diagnosed with CIDP between 2008 and 2018. Overall, 3975 patients with CIDP who received IVIG were included in the study. In the 6 months before starting IVIG, patients frequently had diagnoses of other diseases in addition to their CIDP; these included neuropathy (75% of patients), hypertension (62%), and diabetes (33%). CIDP features and symptoms that affected patients' daily lives were also frequently reported in these 6 months, including long-lasting pain (80%), difficulty walking (30%), and weakness (30%). In the 3 months before starting IVIG treatment, 20% to > 40% of patients underwent diagnostic procedures related to their CIDP. Different IVIG products were used similarly, but the year of IVIG initiation, geographic region, and insurance type all differed by IVIG product. In conclusion, patients with CIDP who receive IVIG experience a heavy burden caused by their symptoms, other diseases, and CIDP-related procedures. Patient characteristics were generally similar between patients receiving different IVIG products, suggesting that no specific characteristics are factored in when doctors select an IVIG product. OABL- eng OTO - NOTNLM OT - Chronic inflammatory demyelinating polyradiculoneuropathy OT - Claims database OT - Intravenous immunoglobulin COIS- J Bradley Layton is an employee of RTI Health Solutions, an organization funded by Takeda to conduct this research. Mary E. Ritchey is a former employee of RTI Health Solutions and is currently affiliated with Med Tech Epi, LLC, Philadelphia, PA, USA, and Center for Pharmacoepidemiology and Treatment Sciences, Rutgers University, New Brunswick, NJ, USA. Zhongwen Huang, Colin Anderson-Smits, and Hakan Ay are employees of Takeda Development Center Americas, Inc., and are Takeda shareholders. Shailesh Chavan was an employee of Takeda Development Center Americas, Inc. at the time of the study and is currently affiliated with Veloxis Pharmaceuticals, Cambridge, MA, USA. Mary E. Ritchey and Nizar Souayah have acted as consultants to Takeda for work outside of this manuscript. EDAT- 2023/05/17 13:09 MHDA- 2023/05/17 13:10 PMCR- 2023/05/17 CRDT- 2023/05/17 11:09 PHST- 2022/12/23 00:00 [received] PHST- 2023/04/05 00:00 [accepted] PHST- 2023/05/17 13:10 [medline] PHST- 2023/05/17 13:09 [pubmed] PHST- 2023/05/17 11:09 [entrez] PHST- 2023/05/17 00:00 [pmc-release] AID - 10.1007/s40120-023-00479-4 [pii] AID - 479 [pii] AID - 10.1007/s40120-023-00479-4 [doi] PST - ppublish SO - Neurol Ther. 2023 Aug;12(4):1171-1186. doi: 10.1007/s40120-023-00479-4. Epub 2023 May 17.